

Applicants: Peter S. Linsley et al.  
U.S. Serial No.: 08/219,200  
Filed: March 29, 1994  
Page 2

Please amend the subject application as follows.

In the Claims:

Please cancel claims 37, 38 and 39 without prejudice to applicants' right to pursue protection for the subject matter defined by these claims if applicants determine to do so in a continuation or divisional application in the future.

Please amend claim 1, 19, 40, and 78 as follows.

- I 1
- 1. (X4 Amended) A method for inhibiting T cell proliferation comprising contacting CD28 positive T cells with B7 antigen [or an anti-CD28 monoclonal antibody] so as to bind the CD28 receptor on the CD28 positive T cells with B7 antigen [or an anti-CD28 monoclonal antibody] and thereby inhibiting T cell proliferation.
- I 2
- 19. (X5 Amended) A method of inhibiting [CD28 positive] T cell-dependent B cell response [proliferation] comprising reacting B7 positive cells with an [monoclonal antibody designated BB-1 or a F(ab)<sub>2</sub> fragment thereof or the exogenous CD28Ig fusion protein and thereby blocking B7-T cell interaction and inhibiting [CD28 positive] T cell-dependent B cell response [proliferation].--
- I 3
- 40. (X2 Amended) The method of claim [39] 19, wherein [said fusion protein is] the CD28Ig fusion protein [corresponding] corresponds to the amino acid sequence encoded by coding region of dna sequence encoding

Applicants: Peter S. Linsley et al.  
U.S. Serial No.: 08/219,200  
Filed: March 29, 1994  
Page 3

73 cd28ig containing plasmid or ecoli having plasmid the  
ecoli designated DNA having ATCC No. 68628--- ecoli  
containing plasmid having... or

74 --78. (Amended) A method of inhibiting [CD28 positive] T  
cell-dependent B cell response [activation] comprising  
reacting B7 positive cells with a CD28 antigen so as to  
bind the B7 positive cells with [the] an exogenous CD28  
antigen thereby inhibiting T cell-dependent B cell  
response [activation].

REMARKS

Claims 1, 3, 5-10, 18-19, 28-32, 37-42, and 78 were pending.  
Claims 37, 38 and 39 have been canceled hereinabove. Claims 1,  
19, 40, and 78 have been amended hereinabove. Accordingly, only  
claims 1, 3, 5-8, 18, 19, 40-42, and 78 are pending and being  
examined.

Support for the changes to claims 19 and 78 may be found in the  
specification as originally filed at page 22, lines 26-27, page  
48, line 22, and pages 12-27. Support for the changes to claims 1  
and 40 may be found in the specification as originally filed at  
page 48, line 22, and pages 12-27. The changes to the claims do  
not involve new matter and applicants respectfully request entry  
of them.